ORIONi003-A
General
Cell Line |
|
| hPSCreg name | ORIONi003-A |
| Cite as: | ORIONi003-A (RRID:CVCL_C9ED) |
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines |
CENSOi003-B (FB79R2c6, CENSOi258) Donor's gene variants: DMD, DMD Donor diseases: Duchenne muscular dystrophy CENSOi005-A (FB76R2c5, CENSOi245) Donor's gene variants: DMD, DMD Donor diseases: Duchenne muscular dystrophy CENSOi007-A (FB75R2c5, CENSOi255) Donor's gene variants: DMD, DMD Donor diseases: Duchenne muscular dystrophy CENSOi001-B (FB78R2c2, CENSOi249) Donor's gene variants: DMD, DMD Donor diseases: Duchenne muscular dystrophy CENSOi002-B (FB74R2c4, CENSOi261) Donor's gene variants: DMD, DMD Donor diseases: Duchenne muscular dystrophy FAMRCi007-A (LMNA #23) Donor's gene variants: LMNA Donor diseases: atrioventricular block Emery-Dreifuss Muscular Dystrophy Paroxysmal atrial fibrillation FAMRCi007-B (LMNA #19) Donor's gene variants: LMNA Donor diseases: atrioventricular block Emery-Dreifuss Muscular Dystrophy Paroxysmal atrial fibrillation FAMRCi005-A (LMNA B4) Donor's gene variants: LMNA Donor diseases: myopathy atrioventricular block Paroxysmal ventricular tachycardia FAMRCi005-B (LMNA B5) Donor's gene variants: LMNA Donor diseases: myopathy atrioventricular block Paroxysmal ventricular tachycardia FAMRCi006-A (LMNA T3) Donor's gene variants: LMNA Donor diseases: Emery-Dreifuss Muscular Dystrophy Dilated Cardiomyopathy FAMRCi006-B (LMNA T4) Donor's gene variants: LMNA Donor diseases: Emery-Dreifuss Muscular Dystrophy Dilated Cardiomyopathy |
| Last update | 27th March 2023 |
| Notes | Our team (Cellphie lab) has developed a new iPSc cell line for modeling Duchenne muscular dystrophy by reprogramming PBMC cells (isolated from pediatric patient) with Sendai virus vector. |
| User feedback | |
Provider |
|
| Generator | Biomedical center Martin, Jessenius Faculty of Medicine in Martin, COMENIUS UNIVERSITY IN BRATISLAVA (ORION) |
| Owner | Biomedical center Martin, Jessenius Faculty of Medicine in Martin, COMENIUS UNIVERSITY IN BRATISLAVA (ORION) |
| Distributors | |
| Derivation country | Slovakia |
External Databases |
|
| BioSamples | SAMEA112765862 |
| Cellosaurus | CVCL_C9ED |
| Wikidata | Q123033218 |
General Information |
|
| Publications |
|
| * Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: not allowed
Commercial use: not allowed
|
Donor Information
General Donor Information |
|
| Sex | male |
| Age of donor (at collection) | 10-14 |
| Ethnicity | White (Caucasian) |
Phenotype and Disease related information (Donor) |
|
| Diseases | A disease was diagnosed.
|
| Disease associated phenotypes | no phenotypes |
| Family history | no family history of disease |
| Is the medical history available upon request? | yes |
| Is clinical information available? | yes |
Karyotyping (Donor) |
|
| Has the donor karyotype been analysed? |
Yes
|
Other Genotyping (Donor) |
|
| Is there genome-wide genotyping or functional data available? |
No
|
External Databases (Donor) |
|
| BioSamples | SAMEA112765863 |
Ethics
| Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
| Was the consent voluntarily given? | Yes |
| Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
| Can you provide us with a copy of the Donor Information Sheet provided to the donor? | Yes |
| Do you (Depositor/Provider) hold the original Donor Consent Form? | Yes |
| Alternatives to consent are available? | No |
| Is there other documentation provided to the donor for consenting purposes? | No |
| Confirm that consent was obtained by a qualified professional | Yes |
| Has the donor agreed to be re-contacted? | Yes |
| Has the donor been informed about how her/his data will be protected? | Yes |
| Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | pseudonymised |
| Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
| Does consent expressly prevent the derivation of pluripotent stem cells? | No |
| Does consent pertain to a specific research project? | No |
| Does consent permit unforeseen future research, without further consent? | Yes |
| Does the consent permit uses of donated embryo/tissue or derived cell line intended for clinical treatment or human applications? | No |
| Does consent expressly prevent development of commercial products? | No |
| Does consent expressly prevent financial gain from any use of the donated embryo/tissue, including any product made from it? | No |
| Does consent expressly permit storage of donated embryo/tissue for an unlimited time? | Yes |
| Does consent expressly permit storage of cells derived from the donated embryo/tissue for an unlimited time? | Yes |
| Does consent prevent the DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
| Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
Does consent permit research by | |
| an academic institution? | Yes |
| a public organisation? | Yes |
| a non-profit company? | Yes |
| a for-profit corporation? | No |
| Does consent expressly permit collection of genetic information? | No |
| Does consent expressly permit storage of genetic information? | No |
| Does consent prevent dissemination of genetic information? | No |
| Has the donor been informed that their donated biosample or derived cells may be tested for the presence of microbiological agents / pathogens? | Yes |
| Has the donor consented to receive information discovered during use of donated embryo/tissue that has significant health implications for the donor? | No |
| How may genetic information associated with the cell line be accessed? | Open Access |
| Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
| Does the consent anticipate that the donor will be notified of results or outcomes of any research involving the donated samples or derived cells? | No |
| Does the consent permit the donor, upon withdrawal of consent, to stop the use of the derived cell line(s) that have already been created from donated samples? | No |
| Does the consent permit the donor, upon withdrawal of consent, to stop delivery or use of information and data about the donor? | No |
| Does consent permit access to medical records of the donor? | Yes |
| Please describe how access is provided: | |
| Does consent permit access to any other source of information about the clinical treatment or health of the donor? | Yes |
| Contact data, institution, or website: | |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
| Name of accrediting authority involved? | (Ethics Committee of Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Slovak Republic) |
| Approval number | Approval number: EK 1856/2016 |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? | Yes |
| Name of accrediting authority involved? | (Ethics Committee of Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Slovak Republic) |
| Approval number | Approval number: EK 1856/2016 |
| Do you have obligations to third parties in regard to the use of the cell line? | No |
| Are you aware of any further constraints on the use of the donated embryo/tissue or derived cells? | No |
| Is there an MTA available for the cell line? | No |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? | ThermoFisher Scientific |
| Are you aware of any constraints on the use or distribution of the cell line from the owner or any parties identified in the query above? | No |
hIPSC Derivation
General |
|
| Source cell type |
A peripheral blood cell with a single nucleus. This category includes lymphocytes and monocytes.
Synonyms
|
| Source cell origin |
A liquid tissue; its major function is to transport oxygen throughout the body. It also supplies the tissues with nutrients, removes waste products, and contains various components of the immune system defending the body against infection. Several hormones also travel in the blood.
Synonyms
|
| Source cell type (free text) | PBMC cells used for reprogramming were isolated from whole blood were isolated using density gradient centrifugation. |
| Age of donor (at collection) | 10-14 |
| Collected in | 2021 |
| Passage number reprogrammed | 7 |
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Sendai virus |
| Is reprogramming vector detectable? |
No |
| Methods used |
PCR
|
| Files and images showing reprogramming vector expressed or silenced | |
Vector free reprogramming |
|
| Type of used vector free reprogramming factor(s) |
mRNA
|
Other |
|
| Selection criteria for clones | Selection criteria were morphology and pluripotent markers expression |
| Derived under xeno-free conditions |
No |
| Derived under GMP? |
No |
| Available as clinical grade? |
No |
Culture Conditions
| Surface coating | Matrigel/Geltrex |
| Feeder cells |
No |
| Passage method | Mechanically |
| O2 Concentration | 20 % |
| CO2 Concentration | 5 % |
| Medium | mTeSR™ 1 |
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | No |
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | No |
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | No |
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| Alkaline Phosphatase |
Yes |
|||||
| NANOG |
Yes |
|||||
| c Myc |
Yes |
|
||||
| Lin-28 |
Yes |
|||||
| SOX2 |
Yes |
|||||
| POU5F1 (OCT-4) |
Yes |
|||||
| SSEA-1 |
No |
|||||
| SSEA-4 |
Yes |
Score:
| Marker | Present | Absent |
| mCpG | ||
| OCT4 |
Morphology pictures
iDMD-1 bright image.tif
Bright images of iDMD-1 iPSc colonies
Differentiation Potency
In vitro directed differentiation
| Marker | Expressed |
| alpha-fetoprotein |
Yes |
Morphology
Endoderm markers for iDMD-1 iPS cell line.tif
ICC of endoderm markers for iDMD-1 iPS cell line
In vitro directed differentiation
| Marker | Expressed |
| alpha smooth muscle actin |
Yes |
Morphology
Mesoderm markers for iDMD-1 iPS cell line.tif
ICC for mesoderm markers for iDMD-1 iPS cell line
In vitro directed differentiation
| Marker | Expressed |
| Class III β-tubulin |
Yes |
Transcriptome data
ICC of ectoderm markers for iDMD-1 iPS cell line
ICC of ectoderm markers for iDMD-1 iPS cell line
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
46,XY normal male karyotype
Passage number: P7
Karyotyping method:
G-Banding
|
Other Genotyping (Cell Line) |
|
Login to share your feedback, experiences or results with the research community.